Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00086827 · ClinicalTrials.gov registry record · Phase 2
Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer
A Phase 2 study of Recurrent Small Cell Lung Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT00086827: Completed Phase 2 study of Recurrent Small Cell Lung Cancer, sponsored by National Cancer Institute (NCI).
NCT00086827 is a Phase 2 study of Recurrent Small Cell Lung Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 36 participants, below the 52-participant average among 5 other Recurrent Small Cell Lung Cancer trials with a reported enrollment target (31% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00086827, a Phase 2 study of Recurrent Small Cell Lung Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well FR901228 works in treating patients with recurrent small cell lung cancer. FR901228 may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
Primary Outcome
95% confidence intervals will be estimated.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG romidepsin
Study Locations (1)
Ohio
- Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2004-05 |
| Phase | Phase 2 |
What the finished NCT00086827 record still lists
NCT00086827 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 52-participant average among 5 other Recurrent Small Cell Lung Cancer trials with a reported enrollment target (31% lower).
The record links to 1 condition, with Recurrent Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00086827 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT00086827 about?
NCT00086827 is a clinical study titled "Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer". This phase II trial is studying how well FR901228 works in treating patients with recurrent small cell lung cancer. FR901228 may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
What is the current status of trial NCT00086827?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2004-05.
What conditions does trial NCT00086827 study?
This clinical trial studies the following conditions: Recurrent Small Cell Lung Cancer.
What interventions are being tested in trial NCT00086827?
The interventions under investigation include: laboratory biomarker analysis (OTHER), romidepsin (DRUG).
Who is sponsoring clinical trial NCT00086827?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00086827 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
COMPLETED · Phase 2
-
Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer
COMPLETED · Phase 2
-
Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
RECRUITING · Phase 1
-
CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
COMPLETED · Phase 1
-
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia